Tasly Pharmaceutical Group (stock code 600535.SH): Clinical trial approved for extending the indication for acute ischemic stroke treated with recombinant human urinary plasminogen activator for injection.

Zhtng Cijng APP News, Tibet Cheezheng (600535.SH) announced that recently, the company's wholly-owned subsidiary Tibet Cheezheng Biopharmaceutical Co., Ltd. ("Tibet Cheezheng Biopharmaceutical") has received approval from the National Medical Products Administration to conduct clinical trials on the company's biopharmaceutical innovative drug injection recombinant human urine prourokinase (Puyouke) with independent intellectual property rights, and to carry out clinical trials for acute ischemic stroke patients who have been ill for 4.5 to 24 hours.